Reproducible RNA vaccine for control of toxoplasmosis and construction method and application thereof

Abstract

The invention relates to a reproducible RNA vaccine for control of toxoplasmosis. The method of the vaccine is as below: inserting a toxoplasmosis antigen gene NTPase-II into an alphavirus vector RREP to obtain a recombinant plasmid pRREP-NTPase-II; and before immunization, conducting in vitro transcription on the recombinant plasmid into RNA to obtain the reproducible RNA vaccine. The invention uses reproducible RNA vaccine for active immunization on BALB/c mice; cellular and humoral immune indexes of the immune mice are determined to evaluate the immunogenicity of the vaccine; through the observation of the survival time of acute Toxoplasma gondii infected mice and count of the number of cysts in brains of chronic Toxoplasma gondii infected mice, the immune protection of the vaccine can be evaluated. The vaccine can effectively enhance the humoral and cellular immune responses, effectively prolong the survival time of the mice after attack by Toxoplasma gondii RH strain (type I), and reduce the formation rate of brain cysts in the immune mice after attack by Toxoplasma gondii PRU strain (type II). The vaccine can be used as an effective candidate vaccine for control of acute and chronic Toxoplasma gondii infectio.

Description

technical field [0001] The invention belongs to the technical field of immunology and molecular biology, in particular to a replicable RNA vaccine for the prevention and treatment of toxoplasmosis and its construction method and application. The vaccine can be used to prevent acute and chronic toxoplasmosis of humans or animals. Background technique [0002] Toxoplasmosis is a zoonotic parasitic disease that seriously endangers the health of the host. The development of safe and effective vaccines is the main strategy for the prevention and treatment of toxoplasmosis. In recent years, research on Toxoplasma gondii vaccines tends to focus on nucleic acid vaccines, and all of them focus on DNA vaccines. However, DNA vaccines have two major disadvantages: ①Due to the barrier effect of the nuclear membrane, DNA vaccines are restricted from entering the nucleus, reducing the immune effect; ②DNA vaccines can be integrated into the host cell nuclear genome, which can induce gene in...

AI Technical Summary

Problems solved by technology

However, DNA vaccines have two major disadvantages: ①Due to the barrier effect of the nuclear membrane, DNA vaccines are restricted from entering the nucleus, reducing the immune effect; ②DNA vaccines can be integrated into the host cell nuclear genome, which can induce gene integration, cell transformation and even tumorigenesis. potential risks

In the face of people's worries and resistance to genetically modified foods, as well as the soundness and improvement of my country's food safety law, these DNA vaccines will not be able to be used for large-scale vaccination and prevention of pigs, sheep and other animals for a long period of time. Difficult to apply to crowd epidemic prevention

Images